| Literature DB >> 6428143 |
Abstract
The experiences of a seven-year study on deprenyl in the treatment of Parkinson's disease are summarized. It was found that the main advantage of deprenyl was that it permitted the reduction of the dose of levodopa in optimally treated patients. In the initial stage of Parkinson's disease deprenyl is only partially sufficient as monotherapy. Deprenyl can administered successfully for correcting the "wearing off" effect.Entities:
Mesh：
Substances：
Year: 1983 PMID： 6428143 DOI： 10.1111/j.1600-0404.1983.tb01525.x
Source DB: PubMed Journal: Acta Neurol Scand Suppl ISSN： 0065-1427